Rajeev Saggar

Chief Tech/Sci/R&D Officer at LIQUIDIA CORPORATION

Net worth: 3 M $ as of 31/03/2024

50 year

Consumer Services

Commercial Services

Profile

Rajeev Saggar is currently the Chief Medical Officer at Liquidia Corp.
Prior to this, he was the Vice President of Clinical Development at Theravance Biopharma US, Inc. from 2021 to 2022.
He also served as the Medical Director for Pulmonary Hypertension & Fibrosis at The Banner-University Medical Center.
Dr. Saggar holds a doctorate degree from the University of California, Irvine.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
LIQUIDIA CORPORATION 0.28%	19/04/2024	211,672 ( 0.28% )	3 M $	31/03/2024

Rajeev Saggar active positions

Companies	Position	Start
LIQUIDIA CORPORATION	Chief Tech/Sci/R&D Officer	18/07/2022

All active positions of Rajeev Saggar

Former positions of Rajeev Saggar

Companies	Position	End
Theravance Biopharma US, Inc. Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA.	Chief Tech/Sci/R&D Officer	01/07/2022
The Banner-University Medical Center	Corporate Officer/Principal	-

See the detail of Rajeev Saggar's experience

Training of Rajeev Saggar

University of California, Irvine

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Rajeev Saggar's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Theravance Biopharma US, Inc. Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA.	Commercial Services
Liquidia Corp.